Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360736 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TP53TDP1TRPA1SRD5A1 | |
| SCHEMBL12015387 | 0.87 | ALDH1A1 (0.42) | ALDH1A1TP53TDP1TRPA1SRD5A1 | |
| SCHEMBL21382587 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TP53TDP1TRPA1SRD5A1 | |
| SCHEMBL1467180 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRMAPTKDM4E | |
| SCHEMBL28356883 | 0.78 | KDM4E (0.35) | MAPTKDM4EL3MBTL1 | |
| SCHEMBL33130 | 0.76 | ALDH1A1 (0.43) | ALDH1A1TP53TDP1TRPA1SRD5A1 | |
| SCHEMBL19831749 | 0.75 | CYP3A4 (0.47) | ALDH1A1TP53TSHRMAPTKDM4E | |
| SCHEMBL30657013 | 0.75 | ALDH1A1 (0.38) | ALDH1A1TDP1MAPTKDM4E | |
| SCHEMBL31122823 | 0.75 | ALDH1A1 (0.48) | ALDH1A1TP53TDP1TRPA1SRD5A1 | |
| SCHEMBL30786494 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4464317-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sumitomo Pharma America, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3494119-B1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-11958862-B2 | Compounds and compositions and uses thereof | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116514761-A | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116283877-A | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110088107-B | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-27 | — | — | US | disclosed |
| US-10196403-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196403-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. | 2018-02-01 | — | — | US | disclosed |
| WO-2018023072-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. | 2018-02-01 | — | — | US | disclosed |
| US-8623590-B2 | Pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-8623590-B2 | Pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120108043-A1 | PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| US-20120108043-A1 | PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196403-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | ALDH1A1 295/4885TP53 4608/4885TDP1 863/4885 |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | ALDH1A1 295/4885TP53 4608/4885TDP1 863/4885 |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | ALDH1A1 231/4885TP53 4616/4885TDP1 387/4885 |
| US-11958862-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | ALDH1A1 295/4885TP53 4608/4885TDP1 863/4885 |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | ALDH1A1 295/4885TP53 4608/4885TDP1 863/4885 |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | ALDH1A1 295/4885TP53 4608/4885TDP1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.